# Butorphanol

## Butaro Nasal Spray 10mg/mL

##### 

| Title              | Content                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
|:-------------------|:----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| TAH Drug Code      | EBUT                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| Indications        | Management of pain when the use of an opioid analgesic is appropriate.                                                                                                                                                                                                                                                                                                                                                                                                |
| Dosing             | Initially 1 mg (1 spray in 1 nostril); if adequate pain relief is not achieved within 60-90 mins， an additional 1 mg dose may be given; may repeat initial dose sequence in 3-4 hr as required after the 2nd dose of the sequence. Alternatively， an initial dose of 2 mg (1 spray in each nostril) may be used in patients who will be able to remain recumbent in the event drowsiness or dizziness occurs; additional 2 mg doses should not be given for 3-4 hr. |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Contraindications  | No Data                                                                                                                                                                                                                                                                                                                                                                                                                                                               |
| Adverse Effects    | Somnolence， dizziness， nausea &/or vomiting， nasal congestion， insomnia.                                                                                                                                                                                                                                                                                                                                                                                          |
| Pregnancy          | Human data suggest risk in 3 rd trimester                                                                                                                                                                                                                                                                                                                                                                                                                             |
| Lactation          | No (Limited) Human Data - Probably Compatible                                                                                                                                                                                                                                                                                                                                                                                                                         |

